Dear Colleagues,

Cell and antibody-based immunotherapy has revolutions cancer care and is a pillar of the standard of care in many cancers. However, the benefit of immunotherapy is limited to a fraction of patients. This limited efficacy is partly due to barriers within the tumor microenvironment (TME) that limit the therapeutic efficacy. 

In this collection, we hope to cover topics related to: (1) elements of the suppressive TME and how they modulate the therapeutic response to various modalities of immunotherapy, (2) ways to exploit elements in the TME or how to reprogram the TME in favor of anti-tumor immunity, and (3)strategies to synergize the immunotherapy with the standard of care using novel technologies or visions that are emerging in the field.